A kinome-wide CRISPR/Cas9 screen in FGFR2-amplified gastric cancer cell lines (e.g., KatoIII) demonstrated that loss of focal adhesion kinase (ILK) and suppression of EGFR/HER2 signaling increased sensitivity to FGFR inhibition. This evidence concerns the gene FGFR2 and gastric cancer.